Botox Articles
Regulatory briefs from GSK/Theravance, Allergan and Mylan
19 December 2012
Migraine drug sales to grow to $5.8 billion in 2021 in major markets
18 November 2012
UK NICE asks for more data on Tarceva, and Botox for migraine
17 February 2012
Pfizer acts to stop Mylan marketing generic Chantix; Allergan in $600 million settlement over Botox marketing practices
2 September 2010
Approval of Allergan’s Botox for migraine “a headache for regulators and payers,” says Datamonitor
30 July 2010
Allergan takes legal action against US govt over right to share info with physicians on Botox
5 October 2009
FDA asks for more info on new Botox indication
28 May 2009
Stock Commentary - Europe - week to April 27, 2009
30 April 2009
Stock Commentary - Europe - week to April 20, 2009
23 April 2009
Galderma/Ipsen's Azzalure cleared in France
2 April 2009
Stock Commentary - New York week to March 30, 2009
2 April 2009
Galderma/Ipsen's Azzalure cleared in the UK
16 March 2009
Stock Commentary - New York week to Feb 16, 2009
23 February 2009
Allergan's 4th-qtr profit falls 6% on 3% sales drop
16 February 2009
Delays for Ipsen BLA as FDA wants more data
12 January 2009
Stock Commentary - Europe - week to Jan 5, 2009
12 January 2009
Allergan may be facing cloud with silver-lining
10 November 2008
Botox sBLA to be filed for chronic migraine
22 September 2008
FDA accepts Reloxin BLA, Ipsen gets $25M
26 May 2008
Ipsen/Medicis submit Reloxin BLA to FDA
24 March 2008
Allergan gets subpoena for Botox promotion
10 March 2008
US FDA opens safety review on Botox
18 February 2008
Allergan's 4th-qtr 17% sales hike still short
14 February 2008
Delay to US NDA for Ipsen/Medicis' Reloxin
11 February 2008
Ipsen and Medicis submit US BLA for Reloxin
10 December 2007
Ipsen and Galderma to co-develop Reloxin in Europe
10 December 2007
Allergan's 3rd-qtr 2007 net income jumps 50%
19 November 2007
Stock Commentary - New York week to August 6, 2007
13 August 2007
Allergan's income soars 86% in 2nd-qtr
13 August 2007
Tanakan may still make reimbursement list
2 April 2007
Allergan buys Groupe Corneal for $217M
13 November 2006
Allergan launches to Juvederm products
2 October 2006
Allergan's 2nd-qtr 2006 profit doubles
14 August 2006
Allergan sees Q1 losses despite sales up 17%
15 May 2006
Japan to discuss pediatric drug use
10 April 2006
Ipsen grants US botox rights to Medicis for $194M
27 March 2006
Ipsen fares well since Bourse listing
27 March 2006
UK MHRA OKs Allergan's Botox agent
27 March 2006
Allergan reports strong 4th-qtr results
13 February 2006
Stock Commentary - New York week to Dec 5
12 December 2005
Study finds Botox potential for urinary incontinence
18 July 2005
France's Ipsen sees 8.6% sales growth
16 May 2005
Stock Commentary - New York
13 December 2004
Allergan 3rd-qtr sales lifted by Botox
15 November 2004
Allergan posts 13.7% leap in 2nd-qtr sales
9 August 2004
Allergan's Botox gets FDA OK for new use
26 July 2004
Allergan bids $230M for Oculex
20 October 2003
Botox injection fails to mask losses at Allergan
4 August 2003
Botox cleared for brow furrow in France
3 March 2003
Botox helps spasticity in stroke victims
12 August 2002
Dermatological drugs to reach $10 billion 2006
20 May 2002
Botox approval could lead to boost in sales
22 April 2002
Positive EU opinion for Allergan's Botox
12 October 2001
Botox cleared for neck pain in USA
2 January 2001
First approval for Elan's Myobloc in USA - revised
14 December 2000
Elan's NeuroBloc backed by CPMP
6 November 2000
Stock Commentary New York
23 March 2000
Allergan launches Alocril in USA
2 March 2000
NeuroBloc effective in cervical dystonia
21 April 1999
Allergan Forecasts Strong 2nd-Qtr Results
9 July 1998
Trend For 1997 Strong Sales Continues In USA
5 February 1998
Allergan Announces R&D Pipeline Developments
5 May 1997
Showing 1-81 of 81 articles
- 1
- Aspen Pharma offers to buy GlaxoSmithKline's thrombosis brands and manufacturing site
- FDA probes two deaths possibly linked to Lilly's antipsychotic Zyprexa Relprevv
- Athera and Boehringer Ingelheim enter option agreement on a novel therapy for atherosclerosis
- US Supreme Court says patent settlement can "sometimes" be illegal
- Actavis and Kissei file law suits against Sandoz and Hetero over Rapaflo patent
